{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:09:22Z","timestamp":1790708962292,"version":"4.1.0"},"reference-count":27,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DML"],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:sec>\n<jats:title> Background:<\/jats:title>\n<jats:p>In healthy volunteers, the probe drug method is widely practised to assess\nthe pharmacokinetic mediated herb-drug interactions (HDI). We analyzed the clinical evidence of\nCYP3 A4 probe drug, Midazolam.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Literatures, where Midazolam was used as a probe drug for prediction of herb-drug interaction,\nwere surveyed through an online database such as google scholar, Scopus, Cochrane,\nPubMed and clinicaltrials.gov.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Midazolam was considered a sensitive probe for CYP3A4 substrates due to its bioavailability.\nWe observed that not all the herbs are causing drug interaction. However, significant\nchanges of the Midazolam pharmacokinetics were found after high-dose and long-term intake of\nsome herbs and food supplements, suggesting the induction and\/or inhibition of CYP activities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Probe drug technique is one of the easiest ways for predicting CYP enzyme-mediated\nherb-drug interactions. Midazolam shows a good response in clinical studies because of short halflife\nand low harmfulness compared with other probe drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872312814666201112122110","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:31:53Z","timestamp":1605241913000},"page":"5-8","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of Herb-drug Interactions Based on the Pharmacokinetic Changes of Probe Drug, Midazolam"],"prefix":"10.2174","volume":"14","author":[{"given":"Sarvesh","family":"Sabarathinam","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, SRM IST, Kattankulathur, Kancheepuram, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangavel M.","family":"Vijayakumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, SRM IST, Kattankulathur, Kancheepuram, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fphar.2013.00177","volume":"4","author":"Ekor M.","year":"2014","unstructured":"Ekor M.; The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014,4(177),177","journal-title":"Front Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1038\/s41598-019-41532-3","volume":"9","author":"Jermini M.","year":"2019","unstructured":"Jermini M.; Dubois J.; Rodondi P.Y.; Zaman K.; Buclin T.; Csajka C.; Orcurto A.; E Rothuizen L.; Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci Rep 2019,9(1),5078","journal-title":"Sci Rep"},{"key":"ref=3","first-page":"274","volume":"11","author":"Shrilatha K.","year":"2019","unstructured":"Shrilatha K.; Prevalence and pattern of use of complementary and alternative medicine in diabetes patients in a south Indian tertiary care teaching hospital. Drug Invent Today 2019,11(2),274-279","journal-title":"Drug Invent Today"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ctcp.2017.12.016","volume":"30","author":"Sarvesh S.","year":"2018","unstructured":"Sarvesh S.; Koushik Muthu Raja M.; Rajanandh M.G.; Seenivasan P.; Prevalence and pattern of usage of complementary and alternative medicine among south Indian asthma patients in a tertiary care hospital. Complement Ther Clin Pract 2018,30(30),103-108","journal-title":"Complement Ther Clin Pract"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5952910","DOI":"10.1155\/2016\/5952910","volume":"2016","author":"Mohd Nor N.H.","year":"2016","unstructured":"Mohd Nor N.H.; Othman F.; Mohd Tohit E.R.; Md Noor S.; Medicinal herbals with antiplatelet properties benefit in coronary atherothrombotic diseases. Thrombosis 2016,2016,5952910","journal-title":"Thrombosis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e0182794","DOI":"10.1371\/journal.pone.0182794","volume":"12","author":"Choi S.","year":"2017","unstructured":"Choi S.; Oh D-S.; Jerng U.M.; A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One 2017,12(8),e0182794","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.pbj.0000000000000015","volume":"4","author":"Borse S.P.","year":"2019","unstructured":"Borse S.P.; Singh D.P.; Nivsarkar M.; Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J 2019,4(2),e15","journal-title":"Porto Biomed J"},{"key":"ref=8","first-page":"347","volume":"13","author":"Wanwimolruk S.","year":"2014","unstructured":"Wanwimolruk S.; Prachayasittikul V.; Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J 2014,13,347-391","journal-title":"EXCLI J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s12272-011-1105-0","volume":"34","author":"Na D.H.","year":"2011","unstructured":"Na D.H.; Ji H.Y.; Park E.J.; Kim M.S.; Liu K-H.; Lee H.S.; Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res 2011,34(11),1829-1842","journal-title":"Arch Pharm Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"Halama B.","year":"2013","unstructured":"Halama B.; Hohmann N.; Burhenne J.; Weiss J.; Mikus G.; Haefeli W.E.; A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 2013,93(6),564-571","journal-title":"Clin Pharmacol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0091270003256059","volume":"43","author":"Veronese M.L.","year":"2003","unstructured":"Veronese M.L.; Gillen L.P.; Burke J.P.; Dorval E.P.; Hauck W.W.; Pequignot E.; Waldman S.A.; Greenberg H.E.; Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003,43(8),831-839","journal-title":"J Clin Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/0091270006292628","volume":"46","author":"Uchida S.","year":"2006","unstructured":"Uchida S.; Yamada H.; Li X.D.; Maruyama S.; Ohmori Y.; Oki T.; Watanabe H.; Umegaki K.; Ohashi K.; Yamada S.; Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006,46(11),1290-1298","journal-title":"J Clin Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1185\/030079908X260871","volume":"24","author":"Robertson S.M.","year":"2008","unstructured":"Robertson S.M.; Davey R.T.; Voell J.; Formentini E.; Alfaro R.M.; Penzak S.R.; Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008,24(2),591-599","journal-title":"Curr Med Res Opin"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"001","DOI":"10.7324\/JAPS.2015.501201","volume":"5","author":"Abdelkawy K.S.","year":"2015","unstructured":"Abdelkawy K.S.; Donia A.; Abdallah M.; Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using Midazolam as CYP3A4 enzyme probe. J App Pharm Sci 2015,5,001-007","journal-title":"J App Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0091270006298359","volume":"47","author":"Farkas D.","year":"2007","unstructured":"Farkas D.; Oleson L.E.; Zhao Y.; Harmatz J.S.; Zinny M.A.; Court M.H.; Greenblatt D.J.; Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007,47(3),286-294","journal-title":"J Clin Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3109\/00498254.2011.644596","volume":"42","author":"Chen Y.","year":"2012","unstructured":"Chen Y.; Ouyang D-S.; Kang Z.; Yang G-P.; Tan Z-R.; Zhou G.; Yan J.; Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers. Xenobiotica 2012,42(6),596-602","journal-title":"Xenobiotica"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.clpt.6100149","volume":"81","author":"Lilja J.J.","year":"2007","unstructured":"Lilja J.J.; Backman J.T.; Neuvonen P.J.; Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007,81(6),833-839","journal-title":"Clin Pharmacol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00228-010-0814-5","volume":"66","author":"Tu J-H.","year":"2010","unstructured":"Tu J-H.; He Y-J.; Chen Y.; Fan L.; Zhang W.; Tan Z-R.; Huang Y.F.; Guo D.; Hu D.L.; Wang D.; Hong-Hao Zhou ; Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol 2010,66(8),805-810","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=19","first-page":"533","volume":"34","author":"Wongnawa M.","year":"2012","unstructured":"Wongnawa M.; The effects of Andrographis paniculata (Burm.f.) Nees on the pharmacokinetics and pharmacodynamics of Midazolam in healthy volunteers. Songklanakarin J Sci Technol 2012,34,533-539","journal-title":"Songklanakarin J Sci Technol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1067\/mcp.2002.126913","volume":"72","author":"Gurley B.J.","year":"2002","unstructured":"Gurley B.J.; Gardner S.F.; Hubbard M.A.; Williams D.K.; Gentry W.B.; Cui Y.; Ang C.Y.W.; Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002,72(3),276-287","journal-title":"Clin Pharmacol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1124\/dmd.112.050203","volume":"41","author":"Doroshyenko O.","year":"2013","unstructured":"Doroshyenko O.; Rokitta D.; Zadoyan G.; Klement S.; Schl\u00e4fke S.; Dienel A.; Gramatt\u00e9 T.; L\u00fcck H.; Fuhr U.; Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 2013,41(5),987-993","journal-title":"Drug Metab Dispos"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0091270011407194","volume":"52","author":"Malati C.Y.","year":"2012","unstructured":"Malati C.Y.; Robertson S.M.; Hunt J.D.; Chairez C.; Alfaro R.M.; Kovacs J.A.; Penzak S.R.; Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol 2012,52(6),932-939","journal-title":"J Clin Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bcp.12496","volume":"79","author":"Teo Y.L.","year":"2015","unstructured":"Teo Y.L.; Ho H.K.; Chan A.; Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015,79(2),241-253","journal-title":"Br J Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1124\/dmd.109.027466","volume":"37","author":"Fisher C.D.","year":"2009","unstructured":"Fisher C.D.; Lickteig A.J.; Augustine L.M.; Ranger-Moore J.; Jackson J.P.; Ferguson S.S.; Cherrington N.J.; Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009,37(10),2087-2094","journal-title":"Drug Metab Dispos"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1872312813666191120094649","volume":"13","author":"Hu S.X.","year":"2019","unstructured":"Hu S.X.; Mazur C.A.; Feenstra K.L.; Assessment of inhibition of bovine hepatic cytochrome P450 by 43 commercial bovine medicines using a combination of in vitro assays and pharmacokinetic data from the literature. Drug Metab Lett 2019,13(2),123-131","journal-title":"Drug Metab Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.5958\/0974-360X.2020.00630.7","volume":"13","author":"Sarvesh Sabarathinam T.M.","year":"2020","unstructured":"Sarvesh Sabarathinam T.M.; Vijayakumar. RP-HPLC Method Development and Validation of Midazolam: A CYP3A4 Probe Drug. Res J Pharm and Tech 2020,13(8),3565-3568","journal-title":"Res J Pharm and Tech"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1872312814666200811110024","volume":"14","author":"Sabarathinam S.","year":"2020","unstructured":"Sabarathinam S.; Vijayakumar T.M.; A short exploration of selected sensitive CYP3A4 substrates (Probe Drug). Drug Metab Lett 2020,14,1","journal-title":"Drug Metab Lett"}],"container-title":["Drug Metabolism Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/187907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187907\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/187907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T14:24:06Z","timestamp":1634480646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187907\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312814666201112122110","relation":{},"ISSN":["1872-3128"],"issn-type":[{"value":"1872-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}